{"id":162355,"date":"2022-05-23T01:48:18","date_gmt":"2022-05-23T05:48:18","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"modified":"2024-08-18T11:44:41","modified_gmt":"2024-08-18T15:44:41","slug":"iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4.php","title":{"rendered":"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)"},"content":{"rendered":"<p><![CDATA[SAN CARLOS, Calif., May  20, 2022  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on May 19, 2022 (the \u201cDate of Grant\u201d), the Company approved the grant of inducement stock options covering an aggregate of 146,700 shares of Iovance\u2019s common stock to 17 new non-executive employees.]]><\/p>\n<p>Here is the original post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/05\/20\/2447950\/0\/en\/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)\">Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Here is the original post: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-162355","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/162355"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=162355"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/162355\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=162355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=162355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=162355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}